Bailard, Inc. Global Blood Therapeutics, Inc. Transaction History

Bailard, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 31, 2020	SELL	$45.7 - $81.86 $228,500 - $409,300	-5,000 Closed	0 $0
Q3 2019 Oct 18, 2019	SELL	$45.35 - $57.91 $2.09 Million - $2.66 Million	-46,000 Reduced 90.2%	5,000 $243,000
Q2 2019 Jul 26, 2019	SELL	$52.6 - $63.29 $678,540 - $816,441	-12,900 Reduced 20.19%	51,000 $2.68 Million
Q1 2019 Apr 24, 2019	BUY	$39.99 - $53.48 $359,910 - $481,320	9,000 Added 16.39%	63,900 $3.38 Million
Q4 2018 Feb 05, 2019	BUY	$31.54 - $46.67 $693,880 - $1.03 Million	22,000 Added 66.87%	54,900 $2.25 Million
Q3 2018 Nov 13, 2018	SELL	$38.0 - $51.1 $288,800 - $388,360	-7,600 Reduced 18.77%	32,900 $1.25 Million
Q2 2018 Aug 08, 2018	SELL	$38.7 - $50.15 $38,700 - $50,150	-1,000 Reduced 2.41%	40,500 $1.83 Million
Q1 2018 May 07, 2018	SELL	$39.6 - $65.9 $1.24 Million - $2.06 Million	-31,200 Reduced 42.92%	41,500 $2 Million
Q4 2017 Feb 08, 2018	BUY	$29.7 - $45.7 $801,900 - $1.23 Million	27,000 Added 59.08%	72,700 $0
Q2 2017 Aug 11, 2017	BUY	N/A	45,700	45,700 $0

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.